GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » Ending Cash Position

Abbott Laboratories (Abbott Laboratories) Ending Cash Position : $6,896 Mil (As of Dec. 2023)


View and export this data going back to 1949. Start your Free Trial

What is Abbott Laboratories Ending Cash Position?

Abbott Laboratories's Ending Cash Position for the quarter that ended in Dec. 2023 was $6,896 Mil.

Abbott Laboratories's quarterly Ending Cash Position declined from Jun. 2023 ($7,835 Mil) to Sep. 2023 ($6,709 Mil) but then increased from Sep. 2023 ($6,709 Mil) to Dec. 2023 ($6,896 Mil).

Abbott Laboratories's annual Ending Cash Position increased from Dec. 2021 ($9,799 Mil) to Dec. 2022 ($9,882 Mil) but then declined from Dec. 2022 ($9,882 Mil) to Dec. 2023 ($6,896 Mil).


Abbott Laboratories Ending Cash Position Historical Data

The historical data trend for Abbott Laboratories's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Ending Cash Position Chart

Abbott Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,860.00 6,838.00 9,799.00 9,882.00 6,896.00

Abbott Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,161.00 7,835.00 6,709.00 6,896.00 -

Abbott Laboratories Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Abbott Laboratories's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=9882+-2986
=6,896

Abbott Laboratories's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=6709+187
=6,896


Abbott Laboratories Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbott Laboratories (Abbott Laboratories) Business Description

Address
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Executives
Andrea F Wainer officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr. officer: VICE PRESIDENT C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone officer: EXECUTIVE VICE PRESIDENT 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau officer: Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady director 50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive officer: Senior Vice President 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt officer: Executive Vice President 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck officer: Vice President, Controller 100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092

Abbott Laboratories (Abbott Laboratories) Headlines

From GuruFocus

Q3 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2019 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024